F-013

Supelco

Fentanyl solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Empirical Formula (Hill Notation):
C22H28N2O
CAS Number:
Molecular Weight:
336.47
MDL number:
PubChem Substance ID:
NACRES:
NA.24

Quality Level

grade

certified reference material

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

concentration

1.0 mg/mL in methanol

Featured Industry

Pharmaceutical (small molecule)

format

single component solution

storage temp.

−20°C

SMILES string

CCC(=O)N(C1CCN(CC1)CCc2ccccc2)c3ccccc3

InChI

1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3

InChI key

PJMPHNIQZUBGLI-UHFFFAOYSA-N

Gene Information

human ... OPRM1(4988)

Looking for similar products? Visit Product Comparison Guide

General description

A potent synthetic narcotic analgesic and local anesthetic with a rapid onset and short duration of action. Sold under various trade names including Sublimaze, Duragesic®, Actiq®, and Fentora®, fentanyl is more potent than morphine in analgesic activity. This certified solution standard is suitable for a variety of LC/MS or GC/MS testing applications from forensic analysis, clinical toxicology, and pain prescription monitoring to urine drug testing and pharmaceutical research.

Legal Information

Actiq is a registered trademark of Anesta Corp.
CERILLIANT is a registered trademark of Cerilliant Corporation
Duragesic is a registered trademark of Johnson & Johnson
Fentora is a registered trademark of Cima Labs, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Cerilliant Corporation

Signal Word

Danger

Target Organs

Eyes

RIDADR

UN1230 - class 3 - PG 2 - Methanol, solution

WGK Germany

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Certificate of Analysis
Certificate of Origin
An EMS guide to chronic pain.
Kevin T Collopy et al.
EMS world, 42(7), 59-63 (2013-08-10)
Nele Plock et al.
International journal of clinical pharmacology and therapeutics, 51(6), 495-508 (2013-04-25)
Intranasal Fentanyl Spray (INFS) was developed for the treatment of breakthrough pain (BTP) in cancer patients using a new route of administration. Dose strengths of 50, 100, and 200 μg INFS (Instanyl®) are currently on the market, however, some adult...
[Pain therapy. Treating pain patients with opioid preparations].
MMW Fortschritte der Medizin, 155(6), 70-71 (2013-05-25)
Terry J Kreeger et al.
Journal of wildlife diseases, 49(3), 674-678 (2013-06-20)
Seven grizzly (Ursus arctos; four male, three female) and three black (Ursus americanus; two male, one female) bears caught in culvert traps or leg snares were immobilized in northwestern Wyoming with carfentanil and xylazine at doses, respectively, of 0.011 ±...
Elzbieta P Wala et al.
Journal of opioid management, 9(2), 85-96 (2013-05-28)
Opioids may cause progressive enhancement of pain sensitivity (opioid-induced hyperalgesia [OIH]) and thus, exacerbate existing pain. Animal studies also demonstrate paradoxical OIH with an ultralow dose (ULD, subanalgesic) of opioid; eg, the μ-opioid, morphine. Repeated administration of ULD-morphine resulted in...
Articles
Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.